A Multi-Center Study Investigating the Correlation Between TARCEVA-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 30 May 2017 Status changed from active, no longer recruiting to completed.
- 02 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 02 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.